Modern Methods of Devic’s Disease Treatment

Authors

  • Grigolashvili Marina Archilovna Department of Neurology, Neurosurgery, Psychiatry and Rehabilitation, Karaganda Medical University, Karaganda, Kazakhstan
  • Kim Ekaterina Danilovna Department of Neurology, Neurosurgery, Psychiatry and Rehabilitation, Karaganda Medical University, Karaganda, Kazakhstan
  • Beisembayeva Mira Baikonyrovna Department of Neurology, Neurosurgery, Psychiatry and Rehabilitation, Karaganda Medical University, Karaganda, Kazakhstan
  • Smagulov Amirzhan Muratovich Department of Neurology, Neurosurgery, Psychiatry and Rehabilitation, Karaganda Medical University, Karaganda, Kazakhstan
  • Omarova Sholpan Kabidenovna Department of Neurology, Neurosurgery, Psychiatry and Rehabilitation, Karaganda Medical University, Karaganda, Kazakhstan
  • Biduysenov Nurdaulet Kurmashovich Department of Neurology, Neurosurgery, Psychiatry and Rehabilitation, Karaganda Medical University, Karaganda, Kazakhstan
  • Belyaev Ruslan Andreevich Department of Neurology, Neurosurgery, Psychiatry and Rehabilitation, Karaganda Medical University, Karaganda, Kazakhstan
  • Abildina Akmaral Ardakovna Department of Neurology, Neurosurgery, Psychiatry and Rehabilitation, Karaganda Medical University, Karaganda, Kazakhstan
  • Abueva Zhanna Argynovna Department of Neurology, Neurosurgery, Psychiatry and Rehabilitation, Karaganda Medical University, Karaganda, Kazakhstan
  • Aimurzina Zhanargul Nagimovna Department of Neurology, Neurosurgery, Psychiatry and Rehabilitation, Karaganda Medical University, Karaganda, Kazakhstan
  • Amanzhol Aigerim Baltalykyzy Department of Neurology, Neurosurgery, Psychiatry and Rehabilitation, Karaganda Medical University, Karaganda, Kazakhstan

DOI:

https://doi.org/10.3889/oamjms.2020.5048

Keywords:

Neuromyelitis optica, Devic’s disease, Optical neuritis, Neuromyelitis optica treatment, Aquaporin

Abstract

BACKGROUND: Neuromyelitis optica (NMO) (also known as opticomyelitis, Devic’s syndrome/disease) is an idiopathic inflammatory disorder of the central nervous system characterized by predominant involvement of the optic nerves, spinal cord, and extensive transverse myelitis. To date, there are no convincing clinical trials that would fully evaluate the efficacy and safety of drugs for the treatment and prevention of NMO exacerbation. Taking into account the malignant course that quickly leads to disability of young, economically active population, the issues of searching for effective methods of NMO treatment remain highly urgent.

AIM: The purpose of the study was to examine available modern methods of treatment and prevention of NMO exacerbation, which have potential and require further detailed clinical trials to ensure possible application of these treatment options in clinical practice.

MATERIALS AND METHODS: We have reviewed previously applied and modern methods of treatment. We have analyzed systematic reviews, clinical, randomized, and retrospective studies of scientific medical databases: PubMed, Cochrane, The Lancet, UpToDate, and reviews of world medical journals in Russian and English.

CONCLUSIONS: The authors concluded that there is a sufficient number of drugs and combinations of methods of Devic’s disease treatment. We were interested in combinations of rituximab (RIT) and autologous stem cell transplantation, RIT and fetal hepatocyte transplantation, and RIT and strengthening the effect by plasmapheresis sessions. However, successful implementation of these methods in clinical practice requires conducting controlled clinical trials with a larger number of patients and longer follow-up periods.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Mironenko TV. Opticomyelitis (Devic’s disease). Scientific review and own clinical observation. Int Neurol J. 2012;71(1):141-7.

Shakhov BE, Belova AN, Shalenkov IV. Opticomyelitis devica: Questions of diagnosis and a description of the case from practice. Med Almanac. 2012:20(1):165-70.

Isaikin AI, Shmidt TE, Yakhno NN. Opticomyelitis. Neurol J. 2014;5:45-51.

Bradl M, Reindl M, Lassmann H. Mechanisms for lesion localization in neuromyelitis optica spectrum disorders. Curr Opin Neurol. 2018;31(3):325-33. https://doi.org/10.1097/wco.0000000000000551 PMid:29465432

Clinical protocol for the diagnosis and treatment of optoneuromyelitis (Devik’s disease) of the Republic of Kazakhstan Protocol code: Code (s) ICD-10:G36.0 Neuromyelitis optic [Devik’s disease] -2015 - http://www.rcrz.kz/docs/clinic_protocol/2015.

Jeffery DR. Early intervention with immunomodulatory agents in the treatment of multiple sclerosis. J Neurol Sci. 2002;197(1-2):1-8. PMid:11997060

Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443-8. https://doi.org/10.1001/archneur.65.11.noc80069 PMid:18779415

Kirgizov KI, Skorobogatova EV, Volkova EY. Experience of the HighDose Chemotherapy followed by Autologous Hematopoietic Stem Cell Transplantation (AutoHSCT) in the Patients with CNS Autoimmune Diseases; 2013.

Kim SH, Kim W, Huh SY, Lee KY, Jung IJ, Kim HJ. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol. 2013;9(1):36-42. https://doi.org/10.3988/jcn.2013.9.1.36 PMid:23346159

A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders.

Tradtrantip L, Asavapanumas N, Phuan P-W, Verkman AS (2014) Potential Therapeutic Benefit of C1-Esterase Inhibitor in Neuromyelitis Optica Evaluated In Vitro and in an Experimental Rat Model. PLoS ONE 9(9): e106824. https://doi.org/10.1371/journal.pone.0106824

Khamidulla AA. Modern aspects of the diagnosis and treatment of multiple sclerosis West Kazakhstan state medical university named after Marat Ospanov. J Neurosurg Neurol Kazakhstan. 2016;1(42):24-9. https://doi.org/10.18484/2305-0047.2018.4.496

Yang Y, Wang CJ, Wang BJ, Zeng ZL, Guo SG. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci. 2018;385:192-7. https://doi.org/10.1016/j.jns.2017.12.034 PMid:29406904

Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: A randomized clinical trial. J Neurol. 2017;264(9):2003-9. https://doi.org/10.1007/s00415-017-8590-0 PMid:28831548

Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, et al. Safety and efficacy of opicinumab in acute optic neuritis: A randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(3):189-99. https://doi.org/10.1016/s1474-4422(16)30377-5

Yamamura T, Kleiter I, Fujihara K, Palace J. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:2114-24. https://doi.org/10.1056/nejmoa1901747

Lotan I, Charlson RW, Ryerson LZ, Levy M, Kister I. Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2020;39:101920. https://doi.org/10.1016/j.msard.2019.101920

Levy M. Plasmapheresis for acute attacks in neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e510. https://doi.org/10.1212/nxi.0000000000000510 PMid:30345335

Kojima M, Oji S, Tanaka S. Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti- AQP4 antibody. Mult Scler Relat Disord. 2019;39:101907. https://doi.org/10.1016/j.msard.2019.101907 PMid:31931404

Cree AC, Bennett JL, Kim J, Weinshenker BG, Pittock SJ. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): A double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352-63. https://doi.org/10.3410/f.736576420.793565143 PMid:31495497

Frampton JE. Correction to: Eculizumab: A review in neuromyelitis optica spectrum disorder. Drugs. 2020;80(7):729. https://doi.org/10.1007/s40265-020-01315-x PMid:32319075

Downloads

Published

2020-10-28

How to Cite

1.
Archilovna GM, Danilovna KE, Baikonyrovna BM, Muratovich SA, Kabidenovna OS, Kurmashovich BN, Andreevich BR, Ardakovna AA, Argynovna AZ, Nagimovna AZ, Baltalykyzy AA. Modern Methods of Devic’s Disease Treatment. Open Access Maced J Med Sci [Internet]. 2020 Oct. 28 [cited 2024 Mar. 28];8(B):1083-7. Available from: https://oamjms.eu/index.php/mjms/article/view/5048